Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elecoglipron in Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Primary completion
- May 2028
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of elecoglipron in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in Hemoglobin A1c at 40 weeks. Started Jul 2026; status: recruiting.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07664553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07664553.